Home › Companies › IMMUNOVANT INC. › 2023-2024
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and IMMUNOVANT INC.’s Form 8-K, filed August 23, 2023 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of August 21, 2023: 5 items on IMMUNOVANT INC.’s Form 8-K, filed August 23, 2023: 2 elected · 2 approved · 1 passed (calculated).
Notable dissent: 3 directors (16.9%, 16.9%, 15.2% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025 2025-2026
Activist investors: Two Seas Capital LP (13F, 2.2%, as of September 30, 2026)
Explore IMMUNOVANT INC. in the interactive database Compare manager voting policies
These tallies are IMMUNOVANT INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed August 23, 2023 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Peter Salzmann, M.D., M.B.A. | 98,532,525 | -- | -- | 17,698,285 | 4,982,266 | 85% | Passed (calculated) | — |
| Elect Director: Douglas Hughes | 96,590,902 | -- | -- | 19,639,908 | 4,982,266 | 83% | Elected | — |
| Elect Director: George Migausky | 96,550,901 | -- | -- | 19,679,909 | 4,982,266 | 83% | Elected | — |
| 2. Ratification of the Selection of Independent Registered Public Accounting Firm | 121,206,460 | 5,261 | 1,355 | -- | -- | 99.9% | Approved | — |
| 3. Approval, on a Non-Binding Advisory Basis, of the Compensation of Immunovant's Named Executive Officers | 115,397,185 | 825,452 | 8,173 | -- | 4,982,266 | 99.3% | Approved | — |
Source: IMMUNOVANT INC., Form 8-K, filed with the SEC on August 23, 2023 — read the filing on EDGAR.
See voting trends for Health Care companies, 2023-2024: shareholder support by sector and by company size.
157 asset managers disclosed a vote on at least one IMMUNOVANT INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
83% Majority: yes · of votes cast
Description as filed by funds: To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2024 Annual Meeting of Stockholders and until the successors are duly elected and qualified: Nominees: Douglas Hughes
IMMUNOVANT INC.’s own tally for this item (“Elect Director: Douglas Hughes”): 96,590,902 for, 19,639,908 withheld, per its Form 8-K filed August 23, 2023 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors Peter Salzmann, M.D., M.B.A., Douglas Hughes and George Migausky were each elected to serve as a member of Immunovant's Board of Directors, or the Board, until the 2024 Annual Meeting of Stockholders and until his successor is duly elected and qualified, or until …”
Support: 83% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 49 asset managers below reported 6,093,893 for, 10,089,147 withheld, 593,838 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,134,554 | 0 | 0 | 23,200 | For |
| Fidelity | 0 | 0 | 0 | 3,969,673 | Withhold |
| State Street | 0 | 0 | 0 | 2,136,788 | Withhold |
| BlackRock | 0 | 0 | 0 | 1,552,132 | Withhold |
| TIAA | 0 | 0 | 0 | 562,500 | Withhold |
| Dimensional | 0 | 0 | 0 | 557,922 | Withhold |
| Victory Capital | 0 | 0 | 0 | 452,381 | Withhold |
| Charles Schwab | 391,552 | 0 | 0 | 0 | For |
| Aberdeen | 336,200 | 0 | 0 | 0 | For |
| JPMorgan | 0 | 0 | 319,087 | 0 | Abstain |
| Bridge Builder Trust | 0 | 0 | 174,411 | 0 | Abstain |
| Equitable | 0 | 0 | 0 | 138,437 | Withhold |
| EA Series Trust | 136,057 | 0 | 0 | 0 | For |
| Prudential/PGIM | 50,550 | 0 | 0 | 60,690 | Mixed |
| ALPS ETF Trust | 0 | 0 | 0 | 95,187 | Withhold |
| Lincoln Financial | 0 | 0 | 26,088 | 68,800 | Mixed |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 75,983 | Withhold |
| ProShares | 0 | 0 | 0 | 60,139 | Withhold |
| Jackson National | 0 | 0 | 54,732 | 0 | Abstain |
| Voya | 0 | 0 | 0 | 53,677 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 0 | 48,012 | Withhold |
| Federated Hermes | 34,649 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 32,832 | Withhold |
| Northern Trust | 0 | 0 | 0 | 29,600 | Withhold |
| New York Life | 0 | 0 | 0 | 26,616 | Withhold |
Showing the 25 largest of 49 asset managers. All 49 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
83% Majority: yes · of votes cast
Description as filed by funds: To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2024 Annual Meeting of Stockholders and until the successors are duly elected and qualified: Nominees: George Migausky
IMMUNOVANT INC.’s own tally for this item (“Elect Director: George Migausky”): 96,550,901 for, 19,679,909 withheld, per its Form 8-K filed August 23, 2023 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors Peter Salzmann, M.D., M.B.A., Douglas Hughes and George Migausky were each elected to serve as a member of Immunovant's Board of Directors, or the Board, until the 2024 Annual Meeting of Stockholders and until his successor is duly elected and qualified, or until …”
Support: 83% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 49 asset managers below reported 6,096,369 for, 10,086,671 withheld, 593,838 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,134,554 | 0 | 0 | 23,200 | For |
| Fidelity | 0 | 0 | 0 | 3,969,673 | Withhold |
| State Street | 0 | 0 | 0 | 2,136,788 | Withhold |
| BlackRock | 0 | 0 | 0 | 1,552,132 | Withhold |
| TIAA | 0 | 0 | 0 | 562,500 | Withhold |
| Dimensional | 0 | 0 | 0 | 557,922 | Withhold |
| Victory Capital | 0 | 0 | 0 | 452,381 | Withhold |
| Charles Schwab | 391,552 | 0 | 0 | 0 | For |
| Aberdeen | 336,200 | 0 | 0 | 0 | For |
| JPMorgan | 0 | 0 | 319,087 | 0 | Abstain |
| Bridge Builder Trust | 0 | 0 | 174,411 | 0 | Abstain |
| Equitable | 0 | 0 | 0 | 138,437 | Withhold |
| EA Series Trust | 136,057 | 0 | 0 | 0 | For |
| Prudential/PGIM | 50,550 | 0 | 0 | 60,690 | Mixed |
| ALPS ETF Trust | 0 | 0 | 0 | 95,187 | Withhold |
| Lincoln Financial | 0 | 0 | 26,088 | 68,800 | Mixed |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 75,983 | Withhold |
| ProShares | 0 | 0 | 0 | 60,139 | Withhold |
| Jackson National | 0 | 0 | 54,732 | 0 | Abstain |
| Voya | 0 | 0 | 0 | 53,677 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 0 | 48,012 | Withhold |
| Federated Hermes | 34,649 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 32,832 | Withhold |
| Northern Trust | 0 | 0 | 0 | 29,600 | Withhold |
| New York Life | 0 | 0 | 0 | 26,616 | Withhold |
Showing the 25 largest of 49 asset managers. All 49 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
85% Majority: yes · of votes cast
Description as filed by funds: To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2024 Annual Meeting of Stockholders and until the successors are duly elected and qualified: Nominees: Peter Salzmann, M.D., M.B.A.
IMMUNOVANT INC.’s own tally for this item (“Elect Director: Peter Salzmann, M.D., M.B.A.”): 98,532,525 for, 17,698,285 withheld, per its Form 8-K filed August 23, 2023 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 49 asset managers below reported 5,533,184 for, 10,668,823 withheld, 574,871 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 0 | 0 | 0 | 5,157,754 | Withhold |
| Fidelity | 27,067 | 0 | 0 | 3,942,606 | Withhold |
| State Street | 2,136,788 | 0 | 0 | 0 | For |
| BlackRock | 1,552,132 | 0 | 0 | 0 | For |
| TIAA | 562,500 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 557,922 | Withhold |
| Victory Capital | 0 | 0 | 0 | 452,381 | Withhold |
| Charles Schwab | 391,552 | 0 | 0 | 0 | For |
| Aberdeen | 336,200 | 0 | 0 | 0 | For |
| JPMorgan | 0 | 0 | 319,087 | 0 | Abstain |
| Bridge Builder Trust | 18,967 | 0 | 155,444 | 0 | Mixed |
| Equitable | 138,437 | 0 | 0 | 0 | For |
| EA Series Trust | 136,057 | 0 | 0 | 0 | For |
| Prudential/PGIM | 50,550 | 0 | 0 | 60,690 | Mixed |
| ALPS ETF Trust | 0 | 0 | 0 | 95,187 | Withhold |
| Lincoln Financial | 37,000 | 0 | 26,088 | 31,800 | Mixed |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 75,983 | Withhold |
| ProShares | 0 | 0 | 0 | 60,139 | Withhold |
| Jackson National | 0 | 0 | 54,732 | 0 | Abstain |
| Voya | 0 | 0 | 0 | 53,677 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 48,012 | 0 | 0 | 0 | For |
| Federated Hermes | 34,649 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 32,832 | Withhold |
| Northern Trust | 29,600 | 0 | 0 | 0 | For |
| New York Life | 0 | 0 | 0 | 26,616 | Withhold |
Showing the 25 largest of 49 asset managers. All 49 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
99.3% Approved · of votes cast
Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation of our named executive officers.
IMMUNOVANT INC.’s own tally for this item (“3. Approval, on a Non-Binding Advisory Basis, of the Compensation of Immunovant's Named Executive Officers”): 115,397,185 for, 825,452 against — passed, per its Form 8-K filed August 23, 2023 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3- Approval, on a Non-Binding Advisory Basis, of the Compensation of Immunovant's Named Executive Officers The stockholders approved, on a non-binding advisory basis, the compensation of Immunovant's named executive officers, as disclosed in the Proxy Statement, including the compensation …”
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,157,754 | 0 | 0 | 0 | For |
| Fidelity | 3,969,673 | 0 | 0 | 0 | For |
| State Street | 2,136,788 | 0 | 0 | 0 | For |
| BlackRock | 1,552,132 | 0 | 0 | 0 | For |
| TIAA | 0 | 562,500 | 0 | 0 | Against |
| Dimensional | 557,922 | 0 | 0 | 0 | For |
| Victory Capital | 452,381 | 0 | 0 | 0 | For |
| Charles Schwab | 391,552 | 0 | 0 | 0 | For |
| Aberdeen | 336,200 | 0 | 0 | 0 | For |
| JPMorgan | 319,087 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 174,411 | 0 | 0 | 0 | For |
| Equitable | 138,437 | 0 | 0 | 0 | For |
| EA Series Trust | 136,057 | 0 | 0 | 0 | For |
| Prudential/PGIM | 111,240 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 95,187 | 0 | 0 | 0 | For |
| Lincoln Financial | 94,888 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 75,983 | 0 | 0 | 0 | For |
| ProShares | 60,139 | 0 | 0 | 0 | For |
| Jackson National | 54,732 | 0 | 0 | 0 | For |
| Voya | 53,677 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 48,012 | 0 | 0 | 0 | For |
| Federated Hermes | 34,649 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 32,832 | 0 | 0 | 0 | For |
| Northern Trust | 29,600 | 0 | 0 | 0 | For |
| New York Life | 26,616 | 0 | 0 | 0 | For |
Fund voting reports, all 49 managers: 16,208,411 for, 568,467 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Deep Track Capital, LP | 5,688,800 | 0 | 0 | 0 | For |
| Fidelity | 5,124,304 | 0 | 0 | 0 | For |
| State Street | 2,993,990 | 0 | 0 | 0 | For |
| Avidity Partners Management LP | 2,155,078 | 0 | 0 | 0 | For |
| Logos Global Management LP | 2,050,000 | 0 | 0 | 0 | For |
| Redmile Group, LLC | 1,728,313 | 0 | 0 | 0 | For |
| BlackRock | 1,604,366 | 0 | 0 | 0 | For |
| PERCEPTIVE ADVISORS LLC | 1,367,104 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,100,117 | 0 | 0 | 0 | For |
| COMMODORE CAPITAL LP | 900,000 | 0 | 0 | 0 | For |
| Victory Capital | 773,855 | 0 | 0 | 0 | For |
| Point72 | 745,938 | 0 | 0 | 0 | For |
| Two Sigma | 569,031 | 0 | 0 | 0 | For |
| Woodline Partners LP | 568,615 | 0 | 0 | 0 | For |
| Nuveen | 0 | 562,883 | 0 | 0 | Against |
| JPMorgan | 535,682 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 500,358 | 0 | 0 | 0 | For |
| PFM Health Sciences, LP | 394,538 | 0 | 0 | 0 | For |
| Charles Schwab | 391,552 | 0 | 0 | 0 | For |
| PLATINUM INVESTMENT MANAGEMENT LTD | 328,842 | 0 | 0 | 0 | For |
| Cormorant Asset Management, LP | 268,759 | 0 | 0 | 0 | For |
| Affinity Asset Advisors, LLC | 259,998 | 0 | 0 | 0 | For |
| DE Shaw | 253,213 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 221,918 | 0 | 0 | 0 | For |
| Dimensional | 214,927 | 0 | 0 | 0 | For |
Institutional-manager reports, all 121 managers: 32,949,798 for, 749,115 against, 8,900 abstained. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Description as filed by funds: To ratify the selection by the Audit Committee of our Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending March 31,2024.
IMMUNOVANT INC.’s own tally for this item (“2. Ratification of the Selection of Independent Registered Public Accounting Firm”): 121,206,460 for, 5,261 against — passed, per its Form 8-K filed August 23, 2023 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Ratification of the Selection of Independent Registered Public Accounting Firm The stockholders ratified the selection by the Audit Committee of the Board of Ernst & Young LLP as Immunovant's independent registered public accounting firm for the year ending March 31, 2024, by the follo…”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 49 asset managers below reported 16,776,878 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,157,754 | 0 | 0 | 0 | For |
| Fidelity | 3,969,673 | 0 | 0 | 0 | For |
| State Street | 2,136,788 | 0 | 0 | 0 | For |
| BlackRock | 1,552,132 | 0 | 0 | 0 | For |
| TIAA | 562,500 | 0 | 0 | 0 | For |
| Dimensional | 557,922 | 0 | 0 | 0 | For |
| Victory Capital | 452,381 | 0 | 0 | 0 | For |
| Charles Schwab | 391,552 | 0 | 0 | 0 | For |
| Aberdeen | 336,200 | 0 | 0 | 0 | For |
| JPMorgan | 319,087 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 174,411 | 0 | 0 | 0 | For |
| Equitable | 138,437 | 0 | 0 | 0 | For |
| EA Series Trust | 136,057 | 0 | 0 | 0 | For |
| Prudential/PGIM | 111,240 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 95,187 | 0 | 0 | 0 | For |
| Lincoln Financial | 94,888 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 75,983 | 0 | 0 | 0 | For |
| ProShares | 60,139 | 0 | 0 | 0 | For |
| Jackson National | 54,732 | 0 | 0 | 0 | For |
| Voya | 53,677 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 48,012 | 0 | 0 | 0 | For |
| Federated Hermes | 34,649 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 32,832 | 0 | 0 | 0 | For |
| Northern Trust | 29,600 | 0 | 0 | 0 | For |
| New York Life | 26,616 | 0 | 0 | 0 | For |
Showing the 25 largest of 49 asset managers. All 49 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 130,565,429 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 3.95% |
| 2 | Fidelity | 3.04% |
| 3 | State Street | 1.64% |
| 4 | BlackRock | 1.19% |
| 5 | TIAA | 0.43% |
| 6 | Dimensional | 0.43% |
| 7 | Victory Capital | 0.35% |
| 8 | Charles Schwab | 0.30% |
| 9 | Aberdeen | 0.26% |
| 10 | JPMorgan | 0.24% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Deep Track Capital, LP | 4.36% |
| 2 | Fidelity | 3.92% |
| 3 | State Street | 2.29% |
| 4 | Avidity Partners Management LP | 1.65% |
| 5 | Logos Global Management LP | 1.57% |
| 6 | Redmile Group, LLC | 1.32% |
| 7 | BlackRock | 1.23% |
| 8 | PERCEPTIVE ADVISORS LLC | 1.05% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 0.84% |
| 10 | COMMODORE CAPITAL LP | 0.69% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Roivant Sciences Ltd. | 79,815,331 | 61.13% | Proxy statement (DEF 14A), proxy filed June 26, 2024 |
| FMR (Fidelity) | 14,729,555 | 11.28% | Form 13F, quarter ended March 31, 2024 |
| FMR LLC | 7,875,822 | 6.03% | Proxy statement (DEF 14A), proxy filed June 26, 2024 |
| Vanguard Group | 6,826,810 | 5.23% | Form 13F, quarter ended March 31, 2024 |
| BlackRock | 5,738,236 | 4.39% | Form 13F, quarter ended March 31, 2024 |
| State Street | 3,641,907 | 2.79% | Form 13F, quarter ended March 31, 2024 |
| Peter Salzmann, M.D., M.B.A. | 3,165,827 | 2.42% | Proxy statement (DEF 14A), proxy filed June 26, 2024 |
| Morgan Stanley | 1,959,026 | 1.50% | Form 13F, quarter ended March 31, 2024 |
| T. Rowe Price | 1,862,043 | 1.43% | Form 13F, quarter ended March 31, 2024 |
| Goldman Sachs | 1,482,539 | 1.14% | Form 13F, quarter ended March 31, 2024 |
Percentages above are of 130,565,429 shares outstanding, as reported by IMMUNOVANT INC. on its Form 10-Q dated June 30, 2023 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At IMMUNOVANT INC.'s shareholder meeting held August 21, 2023, in the 2023-2024 proxy season, 157 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,033 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of our named executive officers. — IMMUNOVANT INC.'s filing reports the proposal as approved, with 99.3% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: IMMUNOVANT INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on August 23, 2023.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from IMMUNOVANT INC.’s 10-Q dated June 30, 2023. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
IMMUNOVANT INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
Proxy Votes Now, “IMMUNOVANT (IMVT) 2023 Annual Meeting (2023-2024 season): Vote Results”, https://proxyvotesnow.com/company/immunovant-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.